The new Histocompatibility and Immunogenetics Laboratory launched its first phase of testing June 26 and ultimately will fully support clinical testing for the Vanderbilt Transplant Center, the nation’s third busiest transplant center by volume.

Preliminary results of a clinical trial of 4-phenylbutyrate (PBA) “show a significant reduction in seizure activity among participants.”

The All of Us Research Program brings the future of health to VUMC and Nashville. 

A real-world learning health system was established at VUMC a decade ago. Now, the National Human Genome Research Institute is awarding two five-year grants totaling $12 million to support VUMC’s participation in, and coordination of, a genomic-enabled learning health system (gLHS) network.

An analysis of genomic data from nearly 250,000 participants in the National Institutes of Health’s All of Us Research Program has identified more than 275 million previously unreported genetic variations, nearly 4 million of which have potential health consequences.

BioVU is celebrating its 15th year and has enabled hundreds of studies and publications exploring the genetic underpinnings of a host of conditions including cancer, heart disease and diabetes. 

Genotyping multiple enzymes that metabolize the immunosuppressive drug tacrolimus — common used for lung transplant recipients — is important for correct dosing of the drug, Vanderbilt researchers found.